|Bid||98.54 x 13500|
|Ask||98.85 x 54600|
|Day's Range||98.33 - 101.26|
|52 Week Range||64.48 - 111.74|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||46.67|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Food and Drug Administration approved an Eli Lilly diabetes drug it described as "novel," prodding LLY stock closer to a breakout.
Bagsværd, Denmark, 16 May 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme initiate
Lilly's (LLY) Mounjaro (tirzepatide) is a novel diabetes treatment, which has shown impressive blood sugar reductions and weight loss in a broad range of type II diabetes patients in the SURPASS studies.